Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Price Pass Below 200 Day Moving Average – Here’s Why

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $30.76 and traded as low as $29.59. Lakefront Biotherapeutics American Depositary Shares shares last traded at $29.60, with a volume of 200,611 shares traded.

Analyst Ratings Changes

LKFT has been the subject of several recent research reports. Morgan Stanley began coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Friday, July 10th. They set an “equal weight” rating and a $30.00 target price for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Finally, Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $34.33.

Lakefront Biotherapeutics American Depositary Shares Stock Up 1.4%

The firm has a market cap of $1.98 billion, a price-to-earnings ratio of -21.28 and a beta of 0.25. The business has a 50 day moving average of $28.64 and a 200 day moving average of $30.75.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of ($1.27) by $1.52. The company had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $11.26 million. Research analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -10.83 earnings per share for the current year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of institutional investors have recently modified their holdings of LKFT. Western Standard LLC purchased a new stake in Lakefront Biotherapeutics American Depositary Shares in the 4th quarter worth approximately $1,046,000. UBS Group AG lifted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 128.4% during the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after purchasing an additional 196,445 shares during the period. Van ECK Associates Corp lifted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% during the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 750 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the third quarter worth $211,000. Finally, Quadrant Capital Group LLC acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the third quarter worth $134,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.